##common.pageHeaderLogo.altText##

Medical guidelines

Vol. 156 No. 1 (2026)

Endocrine care of transgender and gender-diverse adults: Swiss recommendations

Cite this as:
Swiss Med Wkly. 2026;156:5059
Published
26.01.2026

Summary

Transgender and gender-diverse individuals require standardised, evidence-based and culturally sensitive endocrine care. International guidelines such as those from the World Professional Association for Transgender Health (WPATH) and the Endocrine Society provide a strong foundation. These Swiss recommendations build on them and offer context-specific recommendations adapted to Switzerland’s healthcare system, insurance policies and social considerations.

These recommendations were developed by the “Working Group Transgender” of the Swiss Society of Endocrinology and Diabetology (SSED/SGED) in collaboration with multidisciplinary experts. They primarily focus on gender-affirming hormone therapy, including indications, monitoring and long-term management. They also address fertility preservation, bone and sexual health, and relevant psychological and legal aspects.

Interdisciplinary collaboration among endocrinologists, primary care providers, mental health professionals, reproductive specialists and surgeons is recommended to ensure cohesive patient-centred care.

References

  1. 1. Coleman E, Radix AE, Bouman WP, Brown GR, de Vries AL, Deutsch MB, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgender Health. 2022 Sep;23 Suppl 1:S1–259. doi: https://doi.org/10.1080/26895269.2022.2100644
  2. 2. Fiani CN, Han HJ. Navigating identity: Experiences of binary and non-binary transgender and gender non-conforming (TGNC) adults. Int J Transgend. 2018;20(2–3):181–94. doi: https://pubmed.ncbi.nlm.nih.gov/32999605/
  3. 3. D’hoore L, T’Sjoen G. Gender-affirming hormone therapy: an updated literature review with an eye on the future. J Intern Med. 2022 May;291(5):574–92. doi: https://doi.org/10.1111/joim.13441
  4. 4. Cocchetti C, Ristori J, Romani A, Maggi M, Fisher AD. Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. J Clin Med . 2020 Jun 1;9(6). doi: /pmc/articles/PMC7356977/
  5. 5. Gender incongruence and transgender health in the ICD. [cited 2025 Aug 6]. Available from: https://www.who.int/standards/classifications/frequently-asked-questions/gender-incongruence-and-transgender-health-in-the-icd
  6. 6. Fernández Rodríguez M. Gender Incongruence is No Longer a Mental Disorder. J Ment Health Clin Psychol. 2018 Sep;2(5):6–8. doi: https://doi.org/10.29245/2578-2959/2018/5.1157
  7. 7. Nokoff NJ. Medical Interventions for Transgender Youth. [Updated 2022 Jan 19]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. South Dartmouth (MA): MDText.com, Inc.; 2000. Table 2. [DSM-5 Criteria for Gender Dysphoria]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK577212/table/pediat_transgender.T.dsm5_criteria_for_g/
  8. 8. Coleman E, Radix AE, Bouman WP, Brown GR, de Vries AL, Deutsch MB, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgender Health. 2022 Sep;23 Suppl 1:S1–259. 10.1080/26895269.2022.2100644
  9. 9. Ipsos. A 30-Country Ipsos Global Advisor Survey LGBT+ PRIDE 2023. 2023 [cited 2025 Aug 6]; Available from: https://www.ipsos.com/en/pride-month-2023-9-of-adults-identify-as-lgbt
  10. 10. Bouman WP, Schwend AS, Motmans J, Smiley A, Safer JD, Deutsch MB, et al. Language and trans health. International Journal of Transgenderism. 2017 Jan 2;18(1):1–6. doi: https://www.tandfonline.com/doi/abs/10.1080/15532739.2016.1262127
  11. 11. van de Grift TC, Mullender MG, Bouman MB. Shared Decision Making in Gender-Affirming Surgery. Implications for Research and Standards of Care. J Sex Med. 2018 Jun;15(6):813–5. doi: https://doi.org/10.1016/j.jsxm.2018.03.088
  12. 12. Clark BA, Virani A, Marshall SK, Saewyc EM. Conditions for shared decision making in the care of transgender youth in Canada. Health Promot Int. 2021 Apr;36(2):570–80. doi: https://doi.org/10.1093/heapro/daaa043
  13. 13. Rudolph H, Burgermeister N, Schulze J, Gross P, Hbscher E, Garcia Nuez D. Von der Psychopathologisierung zum affirmativen Umgang mit Geschlechtervielfalt. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. 2023. Available from: https://www.researchgate.net/publication/367411586_Von_der_Psychopathologisierung_zum_affirmativen_Umgang_mit_Geschlechtervielfalt doi: https://doi.org/10.4414/smf.2023.09300
  14. 14. SR 210 - Schweizerisches Zivilgesetzbuch vom 10. Dezember 1907. Fedlex. [cited 2025 Aug 6]. Available from: https://www.fedlex.admin.ch/eli/cc/24/233_245_233/de
  15. 15. Die Gruppe Verteidigung. [cited 2025 Aug 6]. Available from: https://www.vtg.admin.ch/de
  16. 16. SR 151.1 - Bundesgesetz vom 24. März 1995 über die Gleichstellung von Frau und Mann (Gleichstellungsgesetz, GlG). Fedlex. [cited 2025 Aug 6]. Available from: https://www.fedlex.admin.ch/eli/cc/1996/1498_1498_1498/de#art_3
  17. 17. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017 Nov;102(11):3869–903. 10.1210/jc.2017-01658
  18. 18. Haupt C, Henke M, Kutschmar A, Hauser B, Baldinger S, Saenz SR, et al. Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women. Cochrane Database Syst Rev. 2020 Nov;11(11):CD013138.
  19. 19. Glintborg D, T’Sjoen G, Ravn P, Andersen MS. MANAGEMENT OF ENDOCRINE DISEASE: optimal feminizing hormone treatment in transgender people. Eur J Endocrinol. 2021 Jun;185(2):R49–63. doi: https://doi.org/10.1530/EJE-21-0059
  20. 20. Kuijpers SM, Wiepjes CM, Conemans EB, Fisher AD, T’Sjoen G, den Heijer M. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study. J Clin Endocrinol Metab. 2021 Sep;106(10):e3936–45. doi: https://doi.org/10.1210/clinem/dgab427
  21. 21. Hayes H, Russell R, Haugen A, Nagavally S, Sarvaideo J. The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone. J Endocr Soc. 2022 Sep;6(11):bvac133. doi: https://doi.org/10.1210/jendso/bvac133
  22. 22. Angus LM, Nolan BJ, Zajac JD, Cheung AS. A systematic review of antiandrogens and feminization in transgender women. Clin Endocrinol (Oxf). 2021 May;94(5):743–52. doi: https://doi.org/10.1111/cen.14329
  23. 23. Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 2017 Apr;5(4):301–11. doi: https://doi.org/10.1016/S2213-8587(16)00036-X
  24. 24. Meriggiola MC, Gava G. Endocrine care of transpeople part I. A review of cross-sex hormonal treatments, outcomes and adverse effects in transmen. Clin Endocrinol (Oxf). 2015 Nov;83(5):597–606. doi: https://doi.org/10.1111/cen.12753
  25. 25. Gava G, Mancini I, Cerpolini S, Baldassarre M, Seracchioli R, Meriggiola MC. Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration. Clin Endocrinol (Oxf). 2018 Dec;89(6):878–86. doi: https://doi.org/10.1111/cen.13821
  26. 26. Wierckx K, Van de Peer F, Verhaeghe E, Dedecker D, Van Caenegem E, Toye K, et al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med. 2014 Jan;11(1):222–9. doi: https://doi.org/10.1111/jsm.12366
  27. 27. Fisher AD, Castellini G, Ristori J, Casale H, Cassioli E, Sensi C, et al. Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data. J Clin Endocrinol Metab. 2016 Nov;101(11):4260–9. doi: https://doi.org/10.1210/jc.2016-1276
  28. 28. van Dijk D, Dekker MJ, Conemans EB, Wiepjes CM, de Goeij EG, Overbeek KA, et al. Explorative Prospective Evaluation of Short-Term Subjective Effects of Hormonal Treatment in Trans People-Results from the European Network for the Investigation of Gender Incongruence. J Sex Med. 2019 Aug;16(8):1297–309. doi: https://doi.org/10.1016/j.jsxm.2019.05.009
  29. 29. Dickersin K, Munro MG, Clark M, Langenberg P, Scherer R, Frick K, et al.; Surgical Treatments Outcomes Project for Dysfunctional Uterine Bleeding (STOP-DUB) Research Group. Hysterectomy compared with endometrial ablation for dysfunctional uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2007 Dec;110(6):1279–89. Available from: https://pubmed.ncbi.nlm.nih.gov/18055721/ doi: https://doi.org/10.1097/01.AOG.0000292083.97478.38
  30. 30. Antun A, Zhang Q, Bhasin S, Bradlyn A, Flanders WD, Getahun D, et al. Longitudinal Changes in Hematologic Parameters Among Transgender People Receiving Hormone Therapy. J Endocr Soc. 2020 Aug;4(11):bvaa119. doi: https://doi.org/10.1210/jendso/bvaa119
  31. 31. Hashemi L, Zhang Q, Getahun D, Jasuja GK, McCracken C, Pisegna J, et al. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy. J Sex Med. 2021 Sep;18(9):1662–75. doi: https://doi.org/10.1016/j.jsxm.2021.06.011
  32. 32. Stangl TA, Wiepjes CM, Defreyne J, Conemans E, D Fisher A, Schreiner T, et al. Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy? Eur J Endocrinol. 2021 Apr;184(4):513–20. doi: https://doi.org/10.1530/EJE-20-1064
  33. 33. Kristensen TT, Christensen LL, Frystyk J, Glintborg D. T’Sjoen G, Roessler KK, et al. Effects of testosterone therapy on constructs related to aggression in transgender men: A systematic review. Horm Behav. 2021 Feb 1;128. https://pubmed.ncbi.nlm.nih.gov/33309817/
  34. 34. Cocchetti C, Ristori J, Romani A, Maggi M, Fisher AD. Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. J Clin Med. 2020 May;9(6):1609. doi: https://doi.org/10.3390/jcm9061609
  35. 35. Riggs DW, Bartholomaeus C. Fertility preservation decision making amongst Australian transgender and non-binary adults. Reprod Health. 2018 Oct;15(1):181. 10.1186/s12978-018-0627-z
  36. 36. Amir H, Yaish I, Oren A, Groutz A, Greenman Y, Azem F. Fertility preservation rates among transgender women compared with transgender men receiving comprehensive fertility counselling. Reprod Biomed Online. 2020 Sep;41(3):546–54. doi: https://doi.org/10.1016/j.rbmo.2020.05.003
  37. 37. Wiepjes CM, Nota NM, de Blok CJ, Klaver M, de Vries AL, Wensing-Kruger SA, et al. The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets. J Sex Med. 2018 Apr;15(4):582–90. doi: https://doi.org/10.1016/j.jsxm.2018.01.016
  38. 38. de Nie I, van Mello NM, Vlahakis E, Cooper C, Peri A, den Heijer M, et al. Successful restoration of spermatogenesis following gender-affirming hormone therapy in transgender women. Cell Rep Med. 2023 Jan;4(1):100858. doi: https://doi.org/10.1016/j.xcrm.2022.100858
  39. 39. Sterling J, Garcia MM. Fertility preservation options for transgender individuals. Transl Androl Urol. 2020 Mar;9(S2 Suppl 2):S215–26. doi: https://doi.org/10.21037/tau.2019.09.28
  40. 40. Cho K, Harjee R, Roberts J, Dunne C. Fertility preservation in a transgender man without prolonged discontinuation of testosterone: a case report and literature review. F S Rep. 2020 Apr;1(1):43–7. doi: https://doi.org/10.1016/j.xfre.2020.03.003
  41. 41. Barbe JE, Del Vento F, Moussaoui D, Crofts VL, Yaron M, Streuli I. Oocyte cryopreservation for fertility preservation in transgender and gender diverse individuals: a SWOT analysis. J Assist Reprod Genet. 2025 Jul:1–9. 10.1007/s10815-025-03579-2
  42. 42. De Roo C, Schneider F, Stolk TH, van Vugt WL, Stoop D, van Mello NM. Fertility in transgender and gender diverse people: systematic review of the effects of gender-affirming hormones on reproductive organs and fertility. Hum Reprod Update. 2025 May;31(3):183–217. 10.1093/humupd/dmae036
  43. 43. Park SU, Sachdev D, Dolitsky S, Bridgeman M, Sauer MV, Bachmann G, et al. Fertility preservation in transgender men and the need for uniform, comprehensive counseling. F S Rep. 2022 Jul;3(3):253–63. doi: https://doi.org/10.1016/j.xfre.2022.07.006
  44. 44. Durcan E, Turan S, Bircan BE, Yaylamaz S, Okur I, Demir AN, et al. Fertility Desire and Motivation Among Individuals with Gender Dysphoria: A Comparative Study. J Sex Marital Ther. 2022;48(8):789–803. doi: https://doi.org/10.1080/0092623X.2022.2053617
  45. 45. Jackson SS, Brown J, Pfeiffer RM, Shrewsbury D, O’Callaghan S, Berner AM, et al. Analysis of Mortality Among Transgender and Gender Diverse Adults in England. JAMA Netw Open. 2023 Jan;6(1):e2253687. doi: https://doi.org/10.1001/jamanetworkopen.2022.53687
  46. 46. de Blok CJ, Wiepjes CM, van Velzen DM, Staphorsius AS, Nota NM, Gooren LJ, et al. Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria. Lancet Diabetes Endocrinol. 2021 Oct;9(10):663–70. doi: https://doi.org/10.1016/S2213-8587(21)00185-6
  47. 47. Robinson IS, Rifkin WJ, Kloer C, Parker A, Blasdel G, Shakir N, et al. Perioperative Hormone Management in Gender-Affirming Mastectomy: Is Stopping Testosterone before Top Surgery Really Necessary? Plast Reconstr Surg. 2023 Feb;151(2):421–7. [cited 2025 Aug 6] Available from: https://www.researchgate.net/publication/365403495_Perioperative_Hormone_Management_in_Gender-Affirming_Mastectomy_Is_Stopping_Testosterone_Before_Top_Surgery_Really_Necessary doi: https://doi.org/10.1097/PRS.0000000000009858
  48. 48. gynécologie suisse. Algorithmen zum Expertenbrief Nr. 50. 2018. Available from: https://www.sggg.ch/fileadmin/user_upload/Formulardaten/Algorithmen_zum_Expertenbrief_Nr_50_D.pdf
  49. 49. Turo R, Jallad S, Prescott S, Cross WR. Metastatic prostate cancer in transsexual diagnosed after three decades of estrogen therapy. Can Urol Assoc J. 2013;7(7-8):E544–6. doi: https://doi.org/10.5489/cuaj.175
  50. 50. Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, et al. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA. 2006 Nov;296(19):2316–7. doi: https://doi.org/10.1001/jama.296.19.2316
  51. 51. Nik-Ahd F, De Hoedt AM, Butler C, Anger JT, Carroll PR, Cooperberg MR, et al. Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen. JAMA. 2024 Jul;332(4):335–7. doi: https://doi.org/10.1001/jama.2024.9997
  52. 52. van Zijverden LM, Wiepjes CM, van Diemen JJ, Thijs A, den Heijer M. Cardiovascular disease in transgender people: a systematic review and meta-analysis. Eur J Endocrinol. 2024 Feb;190(2):S13–24. doi: https://doi.org/10.1093/ejendo/lvad170
  53. 53. Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, Davidge-Pitts CJ, Nippoldt TB, Prokop LJ, et al. Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2017 Nov;102(11):3914–23. doi: https://doi.org/10.1210/jc.2017-01643
  54. 54. Leemaqz SY, Kyinn M, Banks K, Sarkodie E, Goldstein D, Irwig MS. Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy. J Clin Lipidol. 2023;17(1):103–11. doi: https://doi.org/10.1016/j.jacl.2022.11.010
  55. 55. Kcomt L, Evans-Polce RJ, Veliz PT, Boyd CJ, McCabe SE. Use of Cigarettes and E-Cigarettes/Vaping Among Transgender People: Results From the 2015 U.S. Transgender Survey. Am J Prev Med. 2020 Oct;59(4):538–47. doi: https://doi.org/10.1016/j.amepre.2020.03.027
  56. 56. Fredriksen-Goldsen KI, Cook-Daniels L, Kim HJ, Erosheva EA, Emlet CA, Hoy-Ellis CP, et al. Physical and mental health of transgender older adults: an at-risk and underserved population. Gerontologist. 2014 Jun;54(3):488–500. doi: https://doi.org/10.1093/geront/gnt021
  57. 57. Streed CG Jr, Beach LB, Caceres BA, Dowshen NL, Moreau KL, Mukherjee M, et al.; American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; Council on Hypertension; and Stroke Council. Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association. Circulation. 2021 Aug;144(6):e136–48. doi: https://doi.org/10.1161/CIR.0000000000001003
  58. 58. Vlot MC, Wiepjes CM, de Jongh RT, T’Sjoen G, Heijboer AC, den Heijer M. Gender-Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen. J Bone Miner Res. 2019 Oct;34(10):1862–72. doi: https://doi.org/10.1002/jbmr.3762
  59. 59. Van Caenegem E, Wierckx K, Taes Y, Schreiner T, Vandewalle S, Toye K, et al. Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case-controlled study (ENIGI). Eur J Endocrinol. 2015 Feb;172(2):163–71. doi: https://doi.org/10.1530/EJE-14-0586
  60. 60. Rosen HN, Hamnvik OR, Jaisamrarn U, Malabanan AO, Safer JD, Tangpricha V, et al. Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position. J Clin Densitom. 2019;22(4):544–53. doi: https://doi.org/10.1016/j.jocd.2019.07.004
  61. 61. Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, Davidge-Pitts C, Nippoldt TB, Prokop LJ, et al. Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2017 Nov;102(11):3904–13. doi: https://doi.org/10.1210/jc.2017-01642
  62. 62. Fighera TM, Ziegelmann PK, Rasia da Silva T, Spritzer PM. Bone Mass Effects of Cross-Sex Hormone Therapy in Transgender People: Updated Systematic Review and Meta-Analysis. J Endocr Soc. 2019 Mar;3(5):943–64. doi: https://doi.org/10.1210/js.2018-00413
  63. 63. Wiepjes CM, Vlot MC, Klaver M, Nota NM, de Blok CJ, de Jongh RT, et al. Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment: A Multicenter Prospective Observational Study. J Bone Miner Res. 2017 Jun;32(6):1252–60. doi: https://doi.org/10.1002/jbmr.3102
  64. 64. Giacomelli G, Meriggiola MC. Bone health in transgender people: a narrative review. Ther Adv Endocrinol Metab. 2022 May;13:20420188221099346. doi: https://doi.org/10.1177/20420188221099346
  65. 65. Ferrari S, Lippuner K, Lamy O, Meier C. 2020 recommendations for osteoporosis treatment according to fracture risk from the Swiss Association against Osteoporosis (SVGO). Swiss Med Wkly. 2020 Sep;150(3940):w20352. doi: https://doi.org/10.4414/smw.2020.20352
  66. 66. Verroken C, Collet S, Lapauw B, T’Sjoen G. Osteoporosis and Bone Health in Transgender Individuals. Calcif Tissue Int. 2022 May;110(5):615–23. 10.1007/s00223-022-00972-2
  67. 67. Cai X, Hughto JM, Reisner SL, Pachankis JE, Levy BR. Benefit of Gender-Affirming Medical Treatment for Transgender Elders: Later-Life Alignment of Mind and Body. LGBT Health. 2019 Jan;6(1):34–9. doi: https://doi.org/10.1089/lgbt.2017.0262
  68. 68. Collister D, Saad N, Christie E, Ahmed S. Providing Care for Transgender Persons With Kidney Disease: A Narrative Review. Can J Kidney Health Dis. 2021 Jan;8:2054358120985379. doi: https://doi.org/10.1177/2054358120985379
  69. 69. Hancock AB, Siegfriedt LL. Transforming Voice and Communication with Transgender and Gender-Diverse People: An Evidence-Based Process. San Diego (CA): Plural Publishing Inc.; 2020.
  70. 70. Ginsberg BA. Dermatologic care of the transgender patient. Int J Womens Dermatol. 2016 Dec;3(1):65–7. doi: https://doi.org/10.1016/j.ijwd.2016.11.007
  71. 71. Miroshnychenko A, Ibrahim S, Roldan Y, Kulatunga-Moruzi C, Montante S, Couban R, et al. Gender affirming hormone therapy for individuals with gender dysphoria aged <26 years: a systematic review and meta-analysis. Arch Dis Child. 2025 May;110(6):437–45. doi: https://doi.org/10.1136/archdischild-2024-327921
  72. 72. van de Grift TC, Elaut E, Cerwenka SC, Cohen-Kettenis PT, De Cuypere G, Richter-Appelt H, et al. Effects of Medical Interventions on Gender Dysphoria and Body Image: A Follow-Up Study. Psychosom Med. 2017 Sep;79(7):815–23. doi: https://doi.org/10.1097/PSY.0000000000000465
  73. 73. Krakowsky Y, Grober ED. A practical guide to female sexual dysfunction: an evidence-based review for physicians in Canada. Can Urol Assoc J. 2018 Jun;12(6):211–6. doi: https://doi.org/10.5489/cuaj.4907
  74. 74. Steers WD. Pharmacologic treatment of erectile dysfunction. Rev Urol. 2002;4(Suppl 3 Suppl 3):S17–25. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC1476024/
  75. 75. Qaseem A, Humphrey LL, Harris R, Starkey M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Screening pelvic examination in adult women: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014 Jul;161(1):67–72. doi: https://doi.org/10.7326/M14-0701
  76. 76. Bockting WO, Robinson BE, Forberg J, Scheltema K. Evaluation of a sexual health approach to reducing HIV/STD risk in the transgender community. AIDS Care. 2005 Apr;17(3):289–303. 10.1080/09540120412331299825
  77. 77. Aaron KJ, Griner S, Footman A, Boutwell A, Van Der Pol B. Vaginal Swab vs Urine for Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis: A Meta-Analysis. Ann Fam Med. 2023;21(2):172–9. doi: https://doi.org/10.1370/afm.2942
  78. 78. Radix AE, Harris AB, Belkind U, Ting J, Goldstein ZG. Chlamydia trachomatis Infection of the Neovagina in Transgender Women. Open Forum Infect Dis. 2019 Nov;6(11):ofz470. doi: https://doi.org/10.1093/ofid/ofz470
  79. 79. Home: LOVE LIFE - Sex aber sicher. [cited 2025 Aug 6]. Available from: https://lovelife.ch/de
  80. 80. Recommendations of the Swiss Federal Commission for Sexual Health (FCSH) on pre-exposure prophylaxis (PrEP) for HIV prevention. [cited 2025 Aug 6]; Available from: www.who.int/hiv/pub/
  81. 81. PROFA | Contraception transmasculine: un mémo pour les pros. [cited 2025 Aug 6]. Available from: https://www.profa.ch/contraception-transmasculine
  82. 82. Okano SH, Pellicciotta GG, Braga GC. Contraceptive Counseling for the Transgender Patient Assigned Female at Birth. RBGO Gynecology & Obstetrics. 2022 Sep 1;44(9):884. doi: https://doi.org/10.1055/s-0042-1751063
  83. 83. Gelles-Soto D, Ward D, Florio T, Kouzounis K, Salgado CJ. Maximizing surgical outcomes with gender affirming hormone therapy in gender affirmation surgery. J Clin Transl Endocrinol. 2024 May;36:100355. doi: https://doi.org/10.1016/j.jcte.2024.100355
  84. 84. Hontscharuk R, Alba B, Manno C, Pine E, Deutsch MB, Coon D, et al. Perioperative Transgender Hormone Management: Avoiding Venous Thromboembolism and Other Complications. Plast Reconstr Surg. 2021 Apr;147(4):1008–17. doi: https://doi.org/10.1097/PRS.0000000000007786
  85. 85. Kozato A, Fox GW, Yong PC, Shin SJ, Avanessian BK, Ting J, et al. No Venous Thromboembolism Increase Among Transgender Female Patients Remaining on Estrogen for Gender-Affirming Surgery. J Clin Endocrinol Metab. 2021 Mar;106(4):e1586–90. doi: https://doi.org/10.1210/clinem/dgaa966
  86. 86. Herndon J, Gupta N, Davidge-Pitts C, Imhof N, Gonzalez C, Carlson S, et al. Genital Surgery Outcomes Using an Individualized Algorithm for Hormone Management in Transfeminine Individuals. J Clin Endocrinol Metab. 2024 Oct;109(11):2774–83. doi: https://doi.org/10.1210/clinem/dgae269
  87. 87. Salas-Humara C, Sequeira GM, Rossi W, Dhar CP. Gender affirming medical care of transgender youth. Curr Probl Pediatr Adolesc Health Care. 2019 Sep;49(9):100683. doi: https://doi.org/10.1016/j.cppeds.2019.100683
  88. 88. Mellerio H, Jacquin P, Trelles N, Le Roux E, Belanger R, Alberti C, et al. Validation of the “Good2Go”: the first French-language transition readiness questionnaire. Eur J Pediatr. 2020 Jan;179(1):61–71. 10.1007/s00431-019-03450-4
  89. 89. SR 832.102 - Verordnung vom 27. Juni 1995 über die Krankenversicherung (KVV). Fedlex. [cited 2025 Aug 6]. Available from: https://www.fedlex.admin.ch/eli/cc/1995/3867_3867_3867/de
  90. 90. 07 - WZW - SGAIM - SSMIG - SSGIM. [cited 2025 Aug 6]. Available from: https://www.sgaim.ch/de/themen/swissdrg-blog/07-wzw
  91. 91. SCHLUMPF c. SUISSE. [cited 2025 Aug 6]. Available from: https://hudoc.echr.coe.int/fre#{%22itemid%22:[%22001-90476%22]}
  92. 92. Recht | TGNS Transgender Network Switzerland. [cited 2025 Aug 6]. Available from: https://www.tgns.ch/de/information/rechtliches/recht/
  93. 93. Remuneration of medicinal products in individual cases. [cited 2025 Aug 21]. Available from: https://www.bag.admin.ch/de/verguetung-von-arzneimitteln-im-einzelfall
  94. 94. Fedlex. Verordnung über die Krankenversicherung / Ordonnance sur l’assurance-maladie. Available from: https://www.fedlex.admin.ch/eli/cc/1995/3867_3867_3867/de